NCT05469009: Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy |
|
|
| Recruiting | 1 | 15 | US | Aducanumab, Aduhelm, Exablate Model 4000 Type 2, Focused Ultrasound, Lecanemab, Leqembi | Ali Rezai, InSightec | Mild Cognitive Impairment, Alzheimer Disease 1 | 07/29 | 07/29 | | |
